Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer-Reference-Cited by-同舟云学术

Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer

Published:2015-03 Issue:3 Volume:26 Page:497-504
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Scagliotti G.V.,Bondarenko I.,Blackhall F.,Barlesi F.,Hsia T.-C.,Jassem J.,Milanowski J.,Popat S.,Sanchez-Torres J.M.,Novello S.,Benner R.J.,Green S.,Molpus K.,Soria J.-C.,Shepherd F.A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/3/497/16698945/mdu517.pdf

Reference19 articles.

1. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway;Nguyen;Clin Lung Cancer,2009

2. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins;Guix;J Clin Invest,2008

3. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination;Nicholson;Clin Cancer Res,2004

4. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells;Camirand;Breast Cancer Res,2005

5. Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis;Steinbach;Biochem Biophys Res Commun,2004

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extracellular Interactors of the IGF System: Impact on Cancer Hallmarks and Therapeutic Approaches;International Journal of Molecular Sciences;2024-05-29

2. Role of Insulin-like Growth Factor-1 Receptor in Tobacco Smoking-Associated Lung Cancer Development;Biomedicines;2024-03-02

3. The Relationship between IGF Pathway and Acquired Resistance to Tyrosine Kinase Inhibitors in Cancer Therapy;Frontiers in Bioscience-Landmark;2023-08-11

4. XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease;Breast Cancer Research;2023-06-12

5. Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer;Gynecologic Oncology;2023-03